Hypoxia‐induced pathways in breast cancer
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Hypoxia, a common consequence of solid tumor growth in breast cancer and other cancers, serves to propagate a cascade of molecular pathways which include angiogenesis, glycolysis, and alterations in microenvironmental pH. Hypoxia‐inducible factors, heterodimeric DNA binding complexes composed of two subunits, provide critical regulation of this response. This review presents a synopsis of the genes induced by hypoxia in the context of breast cancer and discusses how upregulation of HIF‐1 activity, and the homologous factor HIF‐2, are not only fundamental for the adaptation to hypoxia but also may be critical for tumor progression. Microsc. Res. Tech. 59:41–48, 2002. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“When the intracellular oxygen is normal, HIF-1 subunits are hydroxylated by the enzyme proline hydroxylase, which requires oxygen from this reaction (Ivan et al., 2001; Jaakkola et al., 2001; Epstein et al., 2001; Masson et al., 2001).”
BackgroundSemenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 3×
“The validity of HIF-1 as a critical regulator for many, but not all, genes involved in hypoxia pathways can be verified by the fact that in HIF-1-deficient embryonic stem cells (ES) the hypoxic response is abrogated (Carmeliet et al., 1998; Iyer et al., 1998).”
BackgroundCellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476 · cited 1×
“The validity of HIF-1 as a critical regulator for many, but not all, genes involved in hypoxia pathways can be verified by the fact that in HIF-1-deficient embryonic stem cells (ES) the hypoxic response is abrogated (Carmeliet et al., 1998; Iyer et al., 1998).”
BackgroundHypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300 · cited 2×
“In an experimental model, cells found to be resistant to p53-mediated apoptosis grew selectively in hypoxic areas (Graeber et al., 1996; Hockel et al., 1999).”
BackgroundHuang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113 · cited 1×
“The interaction between these two heterodimers is oxygen-dependent, since in normoxia the ubiquitinproteosome pathway rapidly degrades the alpha subunit (Salcedo and Caro, 1997; Huang et al., 1998; Kallio et al., 1999) (Fig.”
BackgroundSalceda, S., & Caro, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22642 · Cited by 1,674
HIF‐1α is required for solid tumor formation and embryonic vascularization
Ryan, H. E., Lo, J., & Johnson, R. S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3005 · Cited by 1,579
General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.
Wang, G. L., & Semenza, G. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.9.4304 · Cited by 1,468 · cited 2×
“A/ GCGTG, are upregulated in response to hypoxia via a highly conserved pathway (Nagao et al., 1993; Maxwell et al., 1993; Semenza et al., 1991; Wang and Semenza, 1993).”
BackgroundTalks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Self-citation
Cited by
The Role of Hypoxia-Induced Factors in Tumor Progression
Vaupel, P. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90005-10 · Cited by 827
Emami Nejad, A., Najafgholian, S., Rostami, A., Sistani, A., Shojaeifar, S., Esparvarinha, M., Nedaeinia, R., Haghjooy Javanmard, S., Taherian, M., Ahmadlou, M., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-020-01719-5 · Cited by 693
Cancer as a robust system: implications for anticancer therapy
Kitano, H. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1300 · Cited by 456
Weber, C. E., & Kuo, P. C. (2012) · Surgical Oncology · doi:10.1016/j.suronc.2011.09.001 · Cited by 271
Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G., & Powis, G. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.233.3.3 · Cited by 240
Dressman, H. K., Hans, C., Bild, A., Olson, J. A., Rosen, E., Marcom, P. K., Liotcheva, V. B., Jones, E. L., Vujaskovic, Z., Marks, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1447 · Cited by 163
“Hypoxia results in cellular responses and is another riskrelated phenotype that plays roles in tumor development, progression, and therapy responsiveness (2, 3).”
BackgroundCooper, C., Liu, G.-Y., Niu, Y.-L., Santos, S., Murphy, L. C., & Watson, P. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1235 · Cited by 64
Metadata
- Authors
- Goonewardene, T. I., Sowter, H. M., & Harris, A. L.
- Venue
- Microscopy Research and Technique
- Publisher
- Wiley
- Published
- 2002-09-19
- Volume
- 59
- Issue
- 1
- Pages
- 41-48
- ISSN
- 1059-910X (ISSN-L)
- 1097-0029
- OpenAlex
- W2169497014
- Cited by
- 71
- References
- 20
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.